Assessment of Cyto/Genotoxicity of Irinotecan in V79 Cells Using the Comet, Micronucleus, and Chromosome Aberration Assay

Open access

Assessment of Cyto/Genotoxicity of Irinotecan in V79 Cells Using the Comet, Micronucleus, and Chromosome Aberration Assay

Irinotecan is a topoisomerase I interactive agent, widely used in the treatment of metastatic colorectal cancer. The genotoxic effects of the maximum single dose (18 μg mL-1), recommended monotherapy dose (9 μg mL-1), and recommended combined therapy dose (4.5 μg mL-1) of irinotecan were studied on V79 cells using the comet assay, chromosome aberration assay, and micronucleus test. The cells were treated with irinotecan for 2 h or 24 h. The statistical significance of the results was determined using the one-way ANOVA test and a nonparametric Mann Whitney U test. The comet assay did not show dose-dependent or time-dependent effects. The chromosome aberration analysis showed large DNA rearrangements, i.e., chromosome exchanges. Although the exposed cultures showed a significant increase in micronucleated cells in respect to control, no dose-dependent relation was established among the treated cultures. Time-dependent effect was also not observed.

Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.

Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.

Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-38.

Kjeldsen E, Svejstrup JQ, Gromova H, Alsner J, Westergaard O. Camptothecin inhibits both the cleavage and religation reactions of eucaryotic DNA topoisomerase I. J Mol Biol 1992;228:1025-30.

Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003;45:91-108.

Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.

Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.

Rothenberg ML, Kuhn JG, Schaf LJ, Drengler RL, Eckhardt SG, Villalonacalero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Vonhoff DD. Alternative dosing scheduels for Irinotecan. Oncology (Huntington) 1998;12(Suppl 6):68-71.

Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972;32:2643-50.

Irinotecan. USP DI. Vol. 1, Drug information for the health care professional. 20th ed. Englewood (CO): Micromedex Inc.; 2000.

Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.

Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS. Preclinical and clinical results with Irinotecan - extending principles learned in model system to clinical trails design. Oncology (Williston Park). 1998;12(8 Suppl 6):84-93.

Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 1993;84:566-73.

Kopjar N, Želježić D, Lucić Vrdoljak A, Radić B, Ramić S, Milić M, Gamulin M, Pavlica V, Fučić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol 2007;100:403-13.

Sánchez-Alcázar JA, Bradbury DA, Brea-Calvo G, Navas P, Knox AJ. Camptothecin-induced apoptosis in non-small cell lung cancer is independent on cyclooxygenase expression. Apoptosis 2003;8:639-47.

Ciesielski MJ, Fenstermaker RA. Synergistic cytotoxicity, apoptosis and protein linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorilation. J Neurooncol 1999;41:223-34.

Minderman H, Conroy JM, O Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Therap 2005;4:885-900.

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anti-Cancer Drugs 2001;12:741-51.

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroentrol Hepatol 2003;18:1095-100.

Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-7.

Daza P, Torreblanca J, Garcia-Herdugo G, Moreno FJ. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells. Cell Biol Int 2002;26:707-13.

Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002;520:47-56.

Gradzka I, Skierski J, Szumiel I. DNA repair, cell cycle progression and cell death following Camptothecin treatment in two murine lymphoma L5178Y sublines. Cell Biochem Funct 1998;16:239-52.

Ollikainen T, Knuuttila A, Suhonen S, Taavitsainen M, Jekunen A, Mattson K, Linnainmaa K. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs 2000;11:93-9.

Anderson RD, Berger NA. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994;309:109-42.

Voight W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM. Topoisomerase- I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 1998;18(5A):3499-505.

Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;193:27-35.

Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52:1823-9.

Mahabir AG, Benthem Jv, Korsten H, Lynch AM, Bailey L, de Vries A, Hendriksen CF, van Steeg H. Detecting genotoxic effects of potential clastogens: An in vivo study using the transgenic lacZ plasmid and the MutaTM Mouse model. Mutat Res 2008;652:151-7.

Holmström M, Winters V. Micronuclei induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice. Mutagenesis 1992;7:189-93.

Bacher LC, Allen JW, Harrington-Brock K, Campbell JA, Moore MM. Genotoxicity of inhibitors of DNA topoisomerase I (camptothecin) and II (m-ASA) in vivo and in vitro. Mutagenesis 1990;5:541-7.

Hardman WE, Moyer MP, Cameron IL. Consumption of an omege-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983-8.

Aydemir N, Bilaloglu R. Genotoxicity of two anticancer drugs; gentamicine and topotecan, in mouse bone marrow in vivo. Mutat Res 2003;537:43-51.

Attia SM, Aleisa AM, Bakheet SA, Al-Yahya AA, Al-Reyaie SS, Ashour AE, Al-Shabanah OA. Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan and irinotecan. Environ Mol Mutegen 2009;50:145-51.

Archives of Industrial Hygiene and Toxicology

The Journal of Institute for Medical Research and Occupational Health

Journal Information

IMPACT FACTOR 2017: 1.117
5-year IMPACT FACTOR: 1.335

CiteScore 2017: 1.24

SCImago Journal Rank (SJR) 2017: 0.341
Source Normalized Impact per Paper (SNIP) 2017: 0.494

Cited By


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 188 188 24
PDF Downloads 74 74 5